title: Interactions between the mGluR2/3 agonist, LY379268, and cocaine on in vivo neurochemistry and behavior in squirrel monkeys.
abstract: Recent evidence indicates that group II metabotropic glutamate receptors (mGluR2 and mGluR3) may play a role in the pathology of cocaine addiction. The purpose of the current study was to determine the effects of the mGluR2/3 agonist, LY379268, on cocaine-induced changes in DA neurochemistry in nonhuman primates. Furthermore, the current study aimed to determine if changes in DA neurochemistry would correlate with LY379268-induced changes in the behavioral effects of cocaine. In vivo microdialysis was conducted in conscious squirrel monkeys (n=4) in order to monitor cocaine-induced changes in extracellular DA in the caudate nucleus. Separate groups of subjects were trained on a fixed-interval schedule of stimulus termination (n=4) or a second-order schedule of cocaine self-administration (n=5) to characterize the behavioral-stimulant and reinforcing effects, respectively. LY379268 significantly attenuated cocaine-induced increases in DA. LY379268 also significantly attenuated cocaine-induced behavioral-stimulant effects following a short pretreatment time, but not following a longer pretreatment time. Cocaine self-administration was significantly attenuated but only at an intermediate pretreatment dose of LY379268. Moreover, reinstatement of previously extinguished cocaine self-administration was not significantly attenuated by LY379268. Hence, drug interactions on neurochemistry did not correlate well with behavioral measures.
authors.affiliation: Division of Neuroscience, Yerkes National Primate Research Center, Emory University, 954 Gatewood Rd, NE, Atlanta, GA 30329, USA. rbauzo@gmail.com
authors.forename: Rayna M
authors.initials: RM
authors.lastname: Bauzo
authors.forename: Heather L
authors.initials: HL
authors.lastname: Kimmel
authors.forename: Leonard L
authors.initials: LL
authors.lastname: Howell
mesh_terms: D000596:Amino Acids / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000008:administration & dosage / Q000494:pharmacology*; D002421:Caudate Nucleus / Q000187:drug effects / Q000378:metabolism*; D003042:Cocaine / Q000008:administration & dosage / Q000494:pharmacology*; D003213:Conditioning, Psychological / Q000187:drug effects; D004298:Dopamine / Q000378:metabolism*; D018765:Dopamine Uptake Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D018690:Excitatory Amino Acid Agonists / Q000008:administration & dosage / Q000494:pharmacology*; D005108:Extinction, Psychological / Q000187:drug effects; D007262:Infusions, Intravenous; D007273:Injections, Intramuscular; D008297:Male; D017551:Microdialysis; D011930:Reaction Time / Q000187:drug effects; D018094:Receptors, Metabotropic Glutamate / Q000819:agonists; D012055:Reinforcement Schedule; D012453:Saimiri; D012646:Self Administration; D013997:Time Factors
chemical_list: D000596:Amino Acids; D019086:Bridged Bicyclo Compounds, Heterocyclic; D018765:Dopamine Uptake Inhibitors; D018690:Excitatory Amino Acid Agonists; C118218:LY 379268; D018094:Receptors, Metabotropic Glutamate; D003042:Cocaine; D004298:Dopamine
references.citation: Eur J Pharmacol. 1998 Oct 23;359(2-3):139-42
references.pmid: 9832384
references.citation: Neuropharmacology. 2003 Oct;45(5):565-74
references.pmid: 12941370
references.citation: J Neurosci. 1995 May;15(5 Pt 2):3896-904
references.pmid: 7751954
references.citation: J Pharmacol Exp Ther. 1999 Oct;291(1):161-70
references.pmid: 10490900
references.citation: J Pharmacol Exp Ther. 2002 Nov;303(2):608-15
references.pmid: 12388642
references.citation: J Comp Neurol. 2007 Dec 20;505(6):682-700
references.pmid: 17948876
references.citation: Neuropharmacology. 2004 Jul;47(1):1-8
references.pmid: 15165829
references.citation: J Pharmacol Exp Ther. 1999 Apr;289(1):412-6
references.pmid: 10087032
references.citation: Nebr Symp Motiv. 2004;50:57-84
references.pmid: 15160638
references.citation: Annu Rev Pharmacol Toxicol. 1997;37:205-37
references.pmid: 9131252
references.citation: Psychopharmacology (Berl). 2004 Jun;174(1):39-44
references.pmid: 15205877
references.citation: Pharmacol Biochem Behav. 2005 Mar;80(3):481-91
references.pmid: 15740791
references.citation: Amino Acids. 2002;23(1-3):161-2
references.pmid: 12373531
references.citation: J Pharmacol Exp Ther. 2002 Jan;300(1):162-71
references.pmid: 11752112
references.citation: J Comp Neurol. 1993 Sep 8;335(2):252-66
references.pmid: 8227517
references.citation: Neuropharmacology. 2003 May;44(6):717-27
references.pmid: 12681370
references.citation: Synapse. 2005 Sep 1;57(3):123-31
references.pmid: 15945063
references.citation: Biochem Soc Trans. 2000;28(4):297-309
references.pmid: 10961913
references.citation: Neuron. 1994 Nov;13(5):1031-7
references.pmid: 7946343
references.citation: Eur J Pharmacol. 2000 Jul 21;400(2-3):221-4
references.pmid: 10988337
references.citation: J Neurosci. 1996 Feb 15;16(4):1550-60
references.pmid: 8778304
references.citation: Pharmacol Biochem Behav. 2007 Jan;86(1):45-54
references.pmid: 17258302
references.citation: J Neurosci. 2007 Aug 1;27(31):8297-308
references.pmid: 17670976
references.citation: Psychopharmacology (Berl). 2006 Jun;186(2):143-9
references.pmid: 16703399
references.citation: Eur J Neurosci. 2005 Jan;21(1):295-300
references.pmid: 15654869
references.citation: Synapse. 2008 Feb;62(2):154-8
references.pmid: 18000815
references.citation: Brain Res. 2000 Dec 29;887(2):378-84
references.pmid: 11134627
references.citation: Synapse. 2005 Jun 1;56(3):129-34
references.pmid: 15765537
references.citation: J Neurosci. 2002 Oct 15;22(20):9134-41
references.pmid: 12388621
references.citation: Science. 1998 Aug 28;281(5381):1349-52
references.pmid: 9721099
references.citation: J Pharmacol Exp Ther. 2008 Jul;326(1):209-17
references.pmid: 18424625
references.citation: Nat Neurosci. 2003 Jul;6(7):743-9
references.pmid: 12778052
references.citation: Psychopharmacology (Berl). 2003 Aug;168(4):446-54
references.pmid: 12709777
references.citation: Neuropharmacology. 1995 Jan;34(1):1-26
references.pmid: 7623957
references.citation: Neuroreport. 2005 Jun 21;16(9):1013-6
references.pmid: 15931079
references.citation: J Med Chem. 1999 Mar 25;42(6):1027-40
references.pmid: 10090786
references.citation: J Pharmacol Exp Ther. 2006 Feb;316(2):905-13
references.pmid: 16223873
references.citation: Brain Res Brain Res Rev. 1998 May;26(2-3):230-5
references.pmid: 9651535
references.citation: Neuron. 1994 Jul;13(1):55-66
references.pmid: 8043281
references.citation: Psychopharmacology (Berl). 2000 Feb;148(3):299-306
references.pmid: 10755743
references.citation: J Comp Neurol. 1998 Jan 5;390(1):5-19
references.pmid: 9456172
references.citation: J Pharmacol Exp Ther. 2006 Aug;318(2):922-31
references.pmid: 16675638